Gbp2-KO 基因敲除小鼠

下单100%中奖,最高可得千元京东卡
复苏/繁育服务
产品名称

Gbp2-KO 基因敲除小鼠

产品编号

S-KO-02193

品系全称

C57BL/6JCya-Gbp2em1/Cya

品系背景

C57BL/6JCya

品系编号

KOCMP-14469-Gbp2-B6J-VA

品系状态

使用本品系发表的文献需注明: Gbp2-KO 基因敲除小鼠 mice (Strain S-KO-02193) were purchased from Cyagen.
交付类型
周龄
性别
基因型
数量

基本信息

基因研究概述

质控标准

基因
基因全称
guanylate binding protein 2
基因别称
-
染色体号
Chr 3 (Mouse)
转录本 ID
NCBI: NM_010260 | Ensembl: ENSMUST00000165774
修饰方式
全身性基因敲除
靶向范围
Exon 3~11
敲除长度
~14.0 kb
品系说明
该品系是基于策略设计时的数据库信息制作而成,建议您在购买前查询最新的数据库和相关文献,以获取最准确的表型信息。
表型提示
MGI:102772Homozygous inactivation of this gene leads to increased susceptibility to chronic Toxoplasma gondii infection, characterized by an increased parasite burden in the brain.
基因Gbp2,即鸟苷酸结合蛋白2,是一种在宿主免疫反应中发挥关键作用的GTP酶。Gbp2属于GBP(鸟苷酸结合蛋白)家族,该家族成员在多种细胞过程中扮演着重要角色,包括细胞骨架重塑、细胞迁移、炎症反应和抗病毒免疫。Gbp2的活化与多种细胞信号通路的调节密切相关,如Notch信号通路、STAT1信号通路和PI3K/AKT/mTOR信号通路等。

Gbp2在多种疾病的发生发展中发挥着重要作用。在糖尿病肾病(DN)中,Gbp2通过激活Notch1信号通路促进巨噬细胞M1极化,从而加剧炎症反应[1]。在结直肠癌(CRC)中,Gbp2的表达与预后和转移相关,其表达水平与免疫微环境和CD8+ T细胞浸润呈正相关[2]。在脓毒症相关的急性肺损伤(ALI)中,Gbp2在脂多糖(LPS)刺激的巨噬细胞来源的外泌体(L-Exo)中显著上调,并通过激活上皮细胞NLRP3信号通路加速肺损伤[3]。在视网膜病变中,Gbp2通过抑制AKT/mTOR/VEGFA轴来抑制病理性视网膜血管生成[4]。在胃癌中,Gbp2表达与预后相关,并预测免疫治疗反应[5]。在三阴性乳腺癌(TNBC)中,Gbp2通过促进自噬和抑制PI3K/AKT/mTOR通路来增强对紫杉醇的敏感性[6]。在胶质母细胞瘤(GBM)中,Gbp2通过Stat3/纤连蛋白通路促进GBM的侵袭[7],并通过KIF22/EGFR信号通路促进GBM的进展[8]。此外,Gbp2在胶质瘤中的表达与预后相关,并具有免疫相关特征[9]。在胰腺腺癌(PAAD)中,Gbp2的表达与预后和免疫微环境相关,是PAAD的潜在预后生物标志物[10]。

综上所述,Gbp2在多种疾病中发挥着重要作用,包括糖尿病肾病、结直肠癌、脓毒症相关急性肺损伤、视网膜病变、胃癌、三阴性乳腺癌、胶质母细胞瘤和胶质瘤。Gbp2通过多种信号通路调节炎症反应、血管生成、肿瘤细胞生长和侵袭等生物学过程。Gbp2的研究有助于深入理解GTP酶在疾病发生发展中的作用机制,为疾病的治疗和预防提供新的思路和策略。

参考文献:
1. Li, Xiaohui, Liu, Jialu, Zeng, Mengru, Wang, Wenpeng, Xiao, Li. 2023. GBP2 promotes M1 macrophage polarization by activating the notch1 signaling pathway in diabetic nephropathy. In Frontiers in immunology, 14, 1127612. doi:10.3389/fimmu.2023.1127612. https://pubmed.ncbi.nlm.nih.gov/37622120/
2. Wang, Haizhou, Zhou, Yabo, Zhang, Yangyang, Zhao, Qiu, Wang, Fan. . Subtyping of microsatellite stability colorectal cancer reveals guanylate binding protein 2 (GBP2) as a potential immunotherapeutic target. In Journal for immunotherapy of cancer, 10, . doi:10.1136/jitc-2021-004302. https://pubmed.ncbi.nlm.nih.gov/35383115/
3. Huang, Wenhui, Zhang, Yue, Zheng, Bojun, Li, Xu, Meng, Ying. 2023. GBP2 upregulated in LPS-stimulated macrophages-derived exosomes accelerates septic lung injury by activating epithelial cell NLRP3 signaling. In International immunopharmacology, 124, 111017. doi:10.1016/j.intimp.2023.111017. https://pubmed.ncbi.nlm.nih.gov/37812968/
4. Xu, Xiaoxiang, Ding, Xihui, Wang, Zizhuo, Li, Xiaohui, Ren, Zhenhua. 2024. GBP2 inhibits pathological angiogenesis in the retina via the AKT/mTOR/VEGFA axis. In Microvascular research, 154, 104689. doi:10.1016/j.mvr.2024.104689. https://pubmed.ncbi.nlm.nih.gov/38636926/
5. Wang, Yunfei, Pan, Jiadong, An, Fangmei, Qian, Zhengtao, Zhan, Qiang. 2023. GBP2 is a prognostic biomarker and associated with immunotherapeutic responses in gastric cancer. In BMC cancer, 23, 925. doi:10.1186/s12885-023-11308-0. https://pubmed.ncbi.nlm.nih.gov/37784054/
6. Zhang, Weidan, Tang, Xin, Peng, Yang, Liu, Li, Liu, Shengchun. 2024. GBP2 enhances paclitaxel sensitivity in triple‑negative breast cancer by promoting autophagy in combination with ATG2 and inhibiting the PI3K/AKT/mTOR pathway. In International journal of oncology, 64, . doi:10.3892/ijo.2024.5622. https://pubmed.ncbi.nlm.nih.gov/38334171/
7. Yu, Shuye, Yu, Xiaoting, Sun, Lili, Chen, Clark C, Li, Ming. 2020. GBP2 enhances glioblastoma invasion through Stat3/fibronectin pathway. In Oncogene, 39, 5042-5055. doi:10.1038/s41388-020-1348-7. https://pubmed.ncbi.nlm.nih.gov/32518375/
8. Ren, Yeqing, Yang, Biao, Guo, Geng, He, Jianhang, Zhou, Zihan. 2022. GBP2 facilitates the progression of glioma via regulation of KIF22/EGFR signaling. In Cell death discovery, 8, 208. doi:10.1038/s41420-022-01018-0. https://pubmed.ncbi.nlm.nih.gov/35436989/
9. Li, Ren, Wang, Yuan-Yuan, Wang, Shu-Le, Wang, Xiao-Man, Guo, Geng. 2022. GBP2 as a potential prognostic predictor with immune-related characteristics in glioma. In Frontiers in genetics, 13, 956632. doi:10.3389/fgene.2022.956632. https://pubmed.ncbi.nlm.nih.gov/36186425/
10. Liu, Bo, Huang, Rongfei, Fu, Tingting, Xu, Ke, Ren, Tao. 2021. GBP2 as a potential prognostic biomarker in pancreatic adenocarcinoma. In PeerJ, 9, e11423. doi:10.7717/peerj.11423. https://pubmed.ncbi.nlm.nih.gov/34026364/